Prospective randomized comparison between omega-3 fatty acid supplements plus simvastatin versus simvastatin alone in Korean patients with mixed dyslipidemia: Lipoprotein profiles and heart rate variability

European Journal of Clinical Nutrition

Volumn 65, Issue 1, 2011, Pages 110-116

  Kim, Sang Hyun ^a,b   Kim, Min Kyung ^a,c   Lee, Hae Young ^a,d   Kang, Hyun Jae ^a,d   Kim, Yong Jin ^a,d   Kim, Hyo Soo ^a,d  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Seoul National University Hospital Healthcare System Gangnam Center   (South Korea)

^d Seoul National University Hospital   (South Korea)

Author keywords

heart rate variability; lipoproteins; omega 3 fatty acid; statin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEART RATE VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED DYSLIPIDEMIA; MONOTHERAPY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOUTH KOREA; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHOLESTEROL; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FEMALE; HEART RATE; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; SIMVASTATIN; TRIGLYCERIDES;

EID: 78651093442     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2010.195     Document Type: Article

References (25)

1. Calabresi L, Donati D, Pazzucconi F, Sirtori CR, Franceschini G (2000). Omacor in familial combined hyperlipidemia: Effects on lipids and low density lipoprotein subclasses. Atherosclerosis 148, 387-396.
2. Calabresi L, Villa B, Canavesi M, Sirtori CR, James RW, Bernini F et al. (2004). An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism 53, 153-158.
3. Chen GY, Hsiao TJ, Lo HM, Kuo CD (2008). Abdominal obesity is associated with autonomic nervous derangement in healthy Asian obese subjects. Clin Nutr 27, 212-217.
4. Christensen JH, Korup E, Aarøe J, Toft E, Møller J, Rasmussen K et al. (1997). Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction. Am J Cardiol 79, 1670-1673.
5. Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitx RA, et al., for the COMBOS Investigators (2007). Efficacy and Tolerability of Adding Prescription Omega-3 Fatty Acids 4 g/d to Simvastatin 40 mg/d in Hypertriglyceridemic Patients: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study. Clin Ther 29, 1354-1367.
6. Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA et al. (2001). An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 85, 544-548.
7. Geelen A, Zock PL, Swenne CA, Brouwer IA, Schouten EG, Katan MB (2003). Effect of n-3 fatty acids on heart rate variability and baroreflex sensitivity in middle-aged subjects. Am Heart J 146, E4.
8. Gentlesk PJ, Wiley T, Taylor AJ (2005). A prospective evaluation of the effect of simvastatin on heart rate variability in non-ischemic cardiomyopathy. Am Heart J 150, 478-483.
9. Goyens PLL, Mensink RP (2006). Effects of alpha-linolenic acid versus those of EPA/DHA on cardiovascular risk markers in healthy elderly subjects. Eur J Clin Nutr 60, 978-984.
10. Harris WS (1997). n-3 Fatty acids and serum lipoproteins: Human studies. Am J Clin Nutr 65 (suppl), 1645S-1654S.
11. Kabir M, Skurnik G, Naour A, Pechtner V, Meugnier E, Rome S et al. (2007). Treatment for 2 mo with n-3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: A randomized controlled study. Am J Clin Nutr 86, 1670-1679.
12. Kleiger RE, Miller JP, Bigger JT, Moss AJ (1987). Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 59, 256-262.
13. La Rovere MT, Bigger JT, Marcus FI, Mortara A, Schwartz PJ (1998). Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 351, 478-484.
14. Lemaitre RN, King IB, Mozaffarian D, Kuller LH, Tracy RP, Siscovick DS (2003). n-3 Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: The Cardiovascular Health Study. Am J Clin Nutr 77, 319-325.
15. Madsen T, Skou HA, Hansen VE, Fog L, Christensen JH, Toft E et al. (2001). C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. Am J Cardiol 88, 1139-1142.
16. Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR (2008). Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol 102, 429-433.
17. Meredith KG, Horne BD, Pearson RR, Maycock CA, Lappe DL, Anderson JL et al. (2007). Comparison of effects of high (80 mg) versus low (20mg) dose of simvastatin on C-reactive protein and lipoproteins in patients with angiographic evidence of coronary arterial narrowing. Am J Cardiol 99, 149-153.
18. Mozaffarian D, Stein PK, Prineas RJ, Siscovick DS (2008). Dietary fish and omega-3 fatty acid consumption and heart rate variability in US adults. Circulation 117, 1130-1137.
19. Pehlivanidis AN, Athyros VG, Demitriadis DS, Papageorgiou AA, Bouloukos VJ, Kontopoulos AG (2001). Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 157, 463-469.
20. Perkiömäki JS, Huikuri HV, Koistinen JM, Mäkikallio T, Castellanos A, Myerburg RJ (1997). Heart rate variability and dispersion of QT interval in patients with vulnerability to ventricular tachycardia and ventricular fibrillation after previous myocardial infarction. J Am Coll Cardiol 30, 1331-1338.
21. Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM et al. (2002). Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction. Circulation 106, 1447-1452.
22. Riahi S, Schmidt EB, Amanavicius N, Karmisholt J, Jensen HS, Christoffersen RP et al. (2006). The effect of atorvastatin on heart rate variability and lipoproteins in patients treated with coronary bypass surgery. Int J Cardiol 111, 436-441.
23. Szabo BM, Van Veldhuisen DJ, Brouwer J, Haaksma J, Lie KI (1995). Relation between severity of disease and impairment of heart rate variability parameters in patients with chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 76, 713-716.
24. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP et al. (2003). Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: A randomised controlled trial. Lancet 361, 477-485.
25. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al., Japan EPA lipid intervention study (JELIS) Investigators (2007). Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 369, 1090-1098.